Evidence map›Paper›PMID 40437154›Full record

ArticleMedical oncology (Northwood, London, England)2025

Demographic and prognostic factors affecting survival in invasive mucinous adenocarcinoma: a national cancer database analysis.

Michael Richard Demangone, Beau Hsia, Augustus Malan, Catherine Taghizadeh, Mark Moroz, Timothy J Brown

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael Richard DemangoneUniversity of Arizona College of Medicine -Phoenix, Phoenix, AZ, USA. michaeldemangone@arizona.edu.ORCID https://orcid.org/0009-0003-4400-5356
Beau HsiaCreighton University School of Medicine, Phoenix, AZ, USA.
Augustus MalanCreighton University School of Medicine, Phoenix, AZ, USA.
Catherine TaghizadehCreighton University School of Medicine, Phoenix, AZ, USA.
Mark MorozGrand Canyon University, Phoenix, AZ, USA.
Timothy J BrownSimmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive mucinous adenocarcinoma (IMA) is a rare lung tumor with a distinctive histology of goblet and columnar cells characterized by diverse growth patterns. The outcomes and prognosis of IMA are poorly defined owing to its rarity. This study uses the National Cancer Database (NCDB) to study the demographic and prognostic factors affecting the overall survival and mortality rates of IMA patients. We identified IMA patients from the NCDB (2004-2020) using ICD-O-3 code 8253. Time-to-event outcomes were analyzed with Kaplan-Meier, log-rank tests, and Cox regression models to assess factors influencing survival. A total of 6202 IMA patients were identified. Older age was linked to poorer survival (2-year = 53.6%, 5-year = 30.9%, 10-year = 12.4%). Female patients had better survival rates than males (2-year = 70.8% vs. 60.7%, p < 0.001). Lower income (< $46,277 and $46,227-$57,856) and lack of radiation therapy were associated with higher mortality (HR = 1.35, p < 0.001). Medicaid insurance also correlated with worse survival compared to private insurance (HR = 1.46, p < 0.001). Male gender, Black or White race, and lower income brackets were associated with increased mortality in IMA. Further, being insured by Medicaid and not undergoing radiation therapy are associated with poorer survival outcomes.

Indexed as

Adenocarcinoma, MucinousLung NeoplasmsAdultAgedAged, 80 and overDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisSurvival RateUnited StatesAdenocarcinomaDemographic factorsInvasive mucinous adenocarcinomaNCDBPrognostic factorsRare cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.